APRE实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 04:00):

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways...

Stats
今日成交量	2 189.00
平均成交量	32 837.00
市值	29.59M
EPS	$0 ( 2024-04-04 )
下一个收益日期	( $-0.780 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.380
ATR14	$0.0550 (1.01%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Mirza Nadeem Q.	Buy	26 920	Stock Options (Right to Purchase)
2024-05-01	Mirza Nadeem Q.	Buy	6 730	Common Stock
2024-05-01	Mirza Nadeem Q.	Sell	2 250	Stock Option (Right to Buy)
2024-03-28	Hamill John P.	Buy	3 365	Common Stock
2024-03-28	Hamill John P.	Buy	13 460	Stock Options (Right to Buy)

INSIDER POWER
90.02
Last 96 transactions
Buy: 13 035 524 \| Sell: 1 176 966

Aprea Therapeutics Inc 相关性

10 最正相关
VRNA	0.895
TTOO	0.886
EOLS	0.869
STRO	0.863
JD	0.862
REVB	0.861
ASPU	0.86
AVIR	0.858
VREX	0.858
DCGO	0.856

10 最负相关
GOODM	-0.886
SHSP	-0.873
PAE	-0.87
MGTA	-0.853
SGLB	-0.852
KIN	-0.85
EBSB	-0.85
CSII	-0.848
OP	-0.845
SCR	-0.842

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Aprea Therapeutics Inc 财务报表

Annual	2023
营收:	$583 231
毛利润:	$576 178 (98.79 %)
EPS:	$-3.95

FY	2023
营收:	$583 231
毛利润:	$576 178 (98.79 %)
EPS:	$-3.95

FY	2022
营收:	$0
毛利润:	$-186 445 (0.00 %)
EPS:	$-2 714.18

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.740

Financial Reports:

No articles found.

Aprea Therapeutics Inc

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.